Perspective Therapeutics Q2 net loss widens on higher R&D costs

Perspective Therapeutics

10/08/2026 21:32

Overview
US radiopharmaceutical developer's Q2 net loss widened as R&D expenses increased
Company ended Q2 with $237 mln in cash and investments, funding operations into late 2027

Outlook
Company expects Chicago manufacturing site completion in early 2027, Los Angeles site in 2H 2027
Perspective expects cash reserves to fund planned milestones and operations into late 2027

Result Drivers
HIGHER R&D SPENDING - Increased research and development expenses as multiple clinical programs advanced

Company press release: ID:nGNX5GwP0j

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.22
 
Q2 Net Loss
 
$26.79 mln
 
Q2 Net Income from Cont Ops
 
-$26.98 mln
 
Q2 Operating Income
 
-$29.26 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Perspective Therapeutics Inc is $13.00, about 333.3% above its August 7 closing price of $3.00

Reuters Recommended Reads
Aug 10 - Oruka Therapeutics Q2 net loss widens on higher R&D costs
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Aug 10 - Metagenomi Q2 net loss widens cash runway seen through 2027

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)